Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial
Year: 2017
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Institutions: Roozbeh Hospital, Tehran University of Medical Sciences
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2765215453
